HD-OPM Archive
Hashtags

#liverfatsummary

40 posts

Roy Taylor trial: clearing liver and pancreas fat via 8-week low-calorie diet reversed T2D

Sep 01, 2024 · Louis Nervegna ♥ 24 · 💬 22 ↩ 21 Insulin resistance & diabetes

Louis summarizes Roy Taylor's randomized trial in which an 8-week very low calorie liquid diet cleared fat from the liver and pancreas, restoring insulin sensitivity and beta cell function and putting diabetes into remission. Average weight loss needed was about 15 kg (33 lb), followed by a Mediterranean-style maintenance diet. Some patients had a full curative response with pancreas regeneration seen on imaging.

Liver fat is the main driver of insulin resistance, and visceral fat is a visible marker

Sep 24, 2024 · Louis Nervegna ♥ 21 · 💬 25 Insulin resistance & diabetes

Louis reposts a Harvard diabetologist's explanation that in most people fat stored in the liver is the biggest cause of insulin resistance. Losing liver fat by any means dramatically improves it, and weight loss removes liver fat first. Refined starch and sugar-sweetened drinks raise the odds, though excess calories alone can do it. Visible abdominal visceral fat is a simple proxy.

MESA: high Lp(a) raised ASCVD risk 2.34-fold only in people with large waist-to-hip ratio

Oct 18, 2025 · Louis Nervegna ♥ 10 · 💬 5 ↩ 4 Lp(a)

Louis summarizes a MESA cohort analysis in Progress in Cardiovascular Diseases showing waist-to-hip ratio (a visceral-fat and liver-fat proxy) modifies the ASCVD risk of Lp(a), while BMI did not. Lp(a) of 50 mg/dL or more with high WHR carried the excess risk, which mostly vanished when WHR was low. He stresses this is a prospective cohort, so it cannot prove causality, but suggests losing visceral fat is important with high Lp(a).

Semaglutide improved MASH inflammation and fibrosis in the Phase 3 ESSENCE trial

Jun 08, 2025 · Louis Nervegna ♥ 5 · 💬 4 GLP-1 drugs (semaglutide, tirzepatide)

The post argues that liver and pancreas fat drive diabetes, insulin resistance and metabolic syndrome, and that fat leaves the liver early on a diet, which is why GLP-1 drugs work well in fatty liver disease. The shared summary describes the ESSENCE trial of weekly semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2-3 and lists open questions such as cirrhosis and durability.

Diet alone restored pancreas and beta-cell function in a Roy Taylor trial patient

Dec 19, 2025 · Louis Nervegna ♥ 12 Insulin resistance & diabetes

Louis re-shares his post on a patient in Roy Taylor's randomized trial whose advanced type 2 diabetes fully resolved after 2 years, with the pancreas imaging almost back to normal. The intervention was 8 weeks of an 800-calorie meal-replacement diet followed by a normal-calorie Mediterranean diet for maintenance. He argues the liver and pancreas were cleared of fat and that some people get a full curative response, though not everyone.